Targeted Delivery of Doxorubicin Into Tumor Cells by Nanostructured Lipid Carriers Conjugated to Anti-Egfrviii Monoclonal Antibody

Targeted Delivery of Doxorubicin Into Tumor Cells by Nanostructured Lipid Carriers Conjugated to Anti-Egfrviii Monoclonal Antibody Publisher Pubmed

Abdolahpour S¹ ; Toliyat T² ; Omidfar K³ ; Modjtahedi H⁴ ; Wong AJ⁵ ; Rasaee MJ⁶ ; Kashanian S¹ ; Paknejad M¹

Show Affiliations

1. Department of Medical Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
2. Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
3. Biosensor Research Center, Endocrinology and Metabolism Molecular and Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
4. School of Life Science, Faculty of Science, Engineering and Computing, Kingston University, London, United Kingdom
5. Brain Tumor Research Laboratories, Program in Cancer Biology, Stanford University Medical Center, Stanford, CA, United States
6. Department of Medical Biotechnology, School of Medical Sciences, Tarbiat Modarres University, Tehran, Iran

Source: Artificial Cells# Nanomedicine and Biotechnology Published:2018

Abstract

Epidermal growth factor receptor variant III (EGFRvIII) is the most common variant of the EGF receptor in many human tumors. This variant is tumor specific and highly immunogenic, thus, it can be used as a target for targeted drug delivery toward tumor cells. The major aim of this study was to develop an EGFRvIII-mediated drug delivery system by anti-EGFRvIII monoclonal antibody (MAb) conjugated to doxorubicin (Dox)-loaded nanostructured lipid carriers (NLC) to enhance the targeting specificity and cytotoxic effect of Dox on EGFRvIII-overexpressing cell line. In our study, Dox was chosen as a hydrophobic cytotoxic drug and drug-loaded nanostructured lipid carriers (Dox-NLC) was prepared by solvent emulsification/evaporation method. In order to conjugate anti-EGFRvIII MAb to Dox-NLC, DSPE-PEG2000-NHS (1,2-distearoylphosphatidylethanolamine–polyethylene glycol 2000–NHS) was used as a linker. Physicochemical characteristics of antibody conjugated Dox-NLC (MAb-Dox-NLC), including particle size, zeta potential, entrapment efficiency and in vitro Dox release were investigated. Cytotoxicity of MAb-Dox-NLC against NIH-3T3 and HC2 20d2/c (EGFRvIII-transfected NIH-3T3) cell lines was evaluated. The MAb-Dox-NLC appeared to enhance the cytotoxic activity of targeted NLC against HC2 20d2/c cells. The cellular uptake percentage of targeted NLC by HC2 20d2/c cells was higher than that of NIH-3T3 cells, indicating that EGFRvIII can specifically target HC2 20d2/c cells. In conclusion, anti-EGFRvIII MAb-targeted NLC may be considered as an effective nanocarrier for targeted drug delivery. © 2017 Informa UK Limited, trading as Taylor & Francis Group.

Related Docs

View other Related Docs

1. Clinical Applications of Nanomedicine in Cancer Therapy, Drug Discovery Today (2020)

2. Injectable Hydrogel-Based Drug Delivery Systems for Local Cancer Therapy, Drug Discovery Today (2016)

3. Nexus Between in Silico and in Vivo Models to Enhance Clinical Translation of Nanomedicine, Nano Today (2021)

4. Toxicology of Nanobiomaterials, Stem Cell Nanoengineering (2015)

5. Electrospun-Based Systems in Cancer Therapy, Electrospun Materials for Tissue Engineering and Biomedical Applications: Research# Design and Commercialization (2017)

6. The Use of Nanoparticles As a Promising Therapeutic Approach in Cancer Immunotherapy, Artificial Cells# Nanomedicine and Biotechnology (2016)

7. Smart Internal Stimulus-Responsive Nanocarriers for Drug and Gene Delivery, Smart internal stimulus-responsive nanocarriers for drug and gene delivery (2015)

8. A Brief Review on the Application of Nanoparticle Enclosed Herbal Medicine for the Treatment of Infective Endocarditis, Biomedicine and Pharmacotherapy (2017)

Experts (# of related papers)

View all Related Experts

Malihe Paknejad (1)

Fatemeh Atyabi (1)

Style	Citing Format
MLA	Abdolahpour S, et al.. "Targeted Delivery of Doxorubicin Into Tumor Cells by Nanostructured Lipid Carriers Conjugated to Anti-Egfrviii Monoclonal Antibody." Artificial Cells# Nanomedicine and Biotechnology, vol. 46, no. 1, 2018, pp. 89-94.
APA	Abdolahpour S, Toliyat T, Omidfar K, Modjtahedi H, Wong AJ, Rasaee MJ, Kashanian S, Paknejad M (2018). Targeted Delivery of Doxorubicin Into Tumor Cells by Nanostructured Lipid Carriers Conjugated to Anti-Egfrviii Monoclonal Antibody. Artificial Cells# Nanomedicine and Biotechnology, 46(1), 89-94.
Chicago	Abdolahpour S, Toliyat T, Omidfar K, Modjtahedi H, Wong AJ, Rasaee MJ, Kashanian S, Paknejad M. "Targeted Delivery of Doxorubicin Into Tumor Cells by Nanostructured Lipid Carriers Conjugated to Anti-Egfrviii Monoclonal Antibody." Artificial Cells# Nanomedicine and Biotechnology 46, no. 1 (2018): 89-94.
Harvard	Abdolahpour S et al. (2018) 'Targeted Delivery of Doxorubicin Into Tumor Cells by Nanostructured Lipid Carriers Conjugated to Anti-Egfrviii Monoclonal Antibody', Artificial Cells# Nanomedicine and Biotechnology, 46(1), pp. 89-94.
Vancouver	Abdolahpour S, Toliyat T, Omidfar K, Modjtahedi H, Wong AJ, Rasaee MJ, et al.. Targeted Delivery of Doxorubicin Into Tumor Cells by Nanostructured Lipid Carriers Conjugated to Anti-Egfrviii Monoclonal Antibody. Artificial Cells# Nanomedicine and Biotechnology. 2018;46(1):89-94.
BibTex	@article{ author = {Abdolahpour S and Toliyat T and Omidfar K and Modjtahedi H and Wong AJ and Rasaee MJ and Kashanian S and Paknejad M}, title = {Targeted Delivery of Doxorubicin Into Tumor Cells by Nanostructured Lipid Carriers Conjugated to Anti-Egfrviii Monoclonal Antibody}, journal = {Artificial Cells# Nanomedicine and Biotechnology}, volume = {46}, number = {1}, pages = {89-94}, year = {2018} }
RIS	TY - JOUR AU - Abdolahpour S AU - Toliyat T AU - Omidfar K AU - Modjtahedi H AU - Wong AJ AU - Rasaee MJ AU - Kashanian S AU - Paknejad M TI - Targeted Delivery of Doxorubicin Into Tumor Cells by Nanostructured Lipid Carriers Conjugated to Anti-Egfrviii Monoclonal Antibody JO - Artificial Cells# Nanomedicine and Biotechnology VL - 46 IS - 1 SP - 89 EP - 94 PY - 2018 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract